vs

Side-by-side financial comparison of IDT CORP (IDT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.

IDT CORP is the larger business by last-quarter revenue ($322.8M vs $196.9M, roughly 1.6× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs 4.3%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-16.0M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 4.4%).

IDT Corporation is a multinational provider of cloud communications, point of sale systems, unified communications, and financial services foreign exchange services for selected clients. It has units dedicated for businesses and consumers such as the Boss Revolution pre-paid phone cards, headquartered in Newark, New Jersey.

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.

IDT vs PCRX — Head-to-Head

Bigger by revenue
IDT
IDT
1.6× larger
IDT
$322.8M
$196.9M
PCRX
Growing faster (revenue YoY)
PCRX
PCRX
+0.9% gap
PCRX
5.1%
4.3%
IDT
More free cash flow
PCRX
PCRX
$59.4M more FCF
PCRX
$43.5M
$-16.0M
IDT
Faster 2-yr revenue CAGR
PCRX
PCRX
Annualised
PCRX
8.5%
4.4%
IDT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
IDT
IDT
PCRX
PCRX
Revenue
$322.8M
$196.9M
Net Profit
$22.4M
Gross Margin
36.6%
79.5%
Operating Margin
9.6%
1.2%
Net Margin
6.9%
Revenue YoY
4.3%
5.1%
Net Profit YoY
29.6%
EPS (diluted)
$0.89
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDT
IDT
PCRX
PCRX
Q4 25
$322.8M
$196.9M
Q3 25
$316.6M
$179.5M
Q2 25
$302.0M
$181.1M
Q1 25
$303.3M
$168.9M
Q4 24
$309.6M
$187.3M
Q3 24
$308.8M
$168.6M
Q2 24
$299.6M
$178.0M
Q1 24
$296.1M
$167.1M
Net Profit
IDT
IDT
PCRX
PCRX
Q4 25
$22.4M
Q3 25
$16.9M
$5.4M
Q2 25
$21.7M
$-4.8M
Q1 25
$20.3M
$4.8M
Q4 24
$17.2M
Q3 24
$36.8M
$-143.5M
Q2 24
$5.6M
$18.9M
Q1 24
$14.4M
$9.0M
Gross Margin
IDT
IDT
PCRX
PCRX
Q4 25
36.6%
79.5%
Q3 25
36.2%
80.9%
Q2 25
37.1%
77.4%
Q1 25
37.0%
79.7%
Q4 24
34.8%
78.7%
Q3 24
33.1%
76.9%
Q2 24
32.4%
75.1%
Q1 24
32.7%
71.6%
Operating Margin
IDT
IDT
PCRX
PCRX
Q4 25
9.6%
1.2%
Q3 25
6.9%
3.5%
Q2 25
8.8%
4.7%
Q1 25
9.3%
1.2%
Q4 24
7.6%
13.2%
Q3 24
6.5%
-82.8%
Q2 24
3.8%
15.9%
Q1 24
5.4%
7.9%
Net Margin
IDT
IDT
PCRX
PCRX
Q4 25
6.9%
Q3 25
5.3%
3.0%
Q2 25
7.2%
-2.7%
Q1 25
6.7%
2.8%
Q4 24
5.6%
Q3 24
11.9%
-85.1%
Q2 24
1.9%
10.6%
Q1 24
4.9%
5.4%
EPS (diluted)
IDT
IDT
PCRX
PCRX
Q4 25
$0.89
$0.05
Q3 25
$0.67
$0.12
Q2 25
$0.86
$-0.11
Q1 25
$0.80
$0.10
Q4 24
$0.68
$0.38
Q3 24
$1.45
$-3.11
Q2 24
$0.22
$0.39
Q1 24
$0.57
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDT
IDT
PCRX
PCRX
Cash + ST InvestmentsLiquidity on hand
$189.3M
$238.4M
Total DebtLower is stronger
$372.2M
Stockholders' EquityBook value
$320.7M
$693.1M
Total Assets
$654.9M
$1.3B
Debt / EquityLower = less leverage
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDT
IDT
PCRX
PCRX
Q4 25
$189.3M
$238.4M
Q3 25
$226.5M
$246.3M
Q2 25
$199.9M
$445.9M
Q1 25
$142.2M
$493.6M
Q4 24
$148.0M
$484.6M
Q3 24
$164.6M
$453.8M
Q2 24
$139.8M
$404.2M
Q1 24
$141.1M
$325.9M
Total Debt
IDT
IDT
PCRX
PCRX
Q4 25
$372.2M
Q3 25
$376.7M
Q2 25
$580.5M
Q1 25
$583.4M
Q4 24
$585.3M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IDT
IDT
PCRX
PCRX
Q4 25
$320.7M
$693.1M
Q3 25
$305.1M
$727.2M
Q2 25
$286.2M
$757.8M
Q1 25
$271.6M
$798.5M
Q4 24
$260.6M
$778.3M
Q3 24
$246.2M
$749.6M
Q2 24
$214.5M
$879.3M
Q1 24
$211.8M
$892.2M
Total Assets
IDT
IDT
PCRX
PCRX
Q4 25
$654.9M
$1.3B
Q3 25
$626.2M
$1.3B
Q2 25
$600.9M
$1.5B
Q1 25
$575.7M
$1.6B
Q4 24
$554.6M
$1.6B
Q3 24
$550.1M
$1.5B
Q2 24
$517.3M
$1.6B
Q1 24
$521.8M
$1.6B
Debt / Equity
IDT
IDT
PCRX
PCRX
Q4 25
0.54×
Q3 25
0.52×
Q2 25
0.77×
Q1 25
0.73×
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDT
IDT
PCRX
PCRX
Operating Cash FlowLast quarter
$-10.1M
$43.7M
Free Cash FlowOCF − Capex
$-16.0M
$43.5M
FCF MarginFCF / Revenue
-4.9%
22.1%
Capex IntensityCapex / Revenue
1.8%
0.1%
Cash ConversionOCF / Net Profit
-0.45×
TTM Free Cash FlowTrailing 4 quarters
$95.4M
$136.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDT
IDT
PCRX
PCRX
Q4 25
$-10.1M
$43.7M
Q3 25
$31.0M
$60.8M
Q2 25
$75.7M
$12.0M
Q1 25
$20.2M
$35.5M
Q4 24
$164.0K
$33.1M
Q3 24
$25.4M
$53.9M
Q2 24
$9.5M
$53.2M
Q1 24
$28.4M
$49.1M
Free Cash Flow
IDT
IDT
PCRX
PCRX
Q4 25
$-16.0M
$43.5M
Q3 25
$25.7M
$57.0M
Q2 25
$70.3M
$9.3M
Q1 25
$15.3M
$26.9M
Q4 24
$-5.1M
$31.0M
Q3 24
$20.1M
$49.8M
Q2 24
$4.7M
$51.6M
Q1 24
$23.9M
$46.3M
FCF Margin
IDT
IDT
PCRX
PCRX
Q4 25
-4.9%
22.1%
Q3 25
8.1%
31.7%
Q2 25
23.3%
5.1%
Q1 25
5.1%
15.9%
Q4 24
-1.7%
16.6%
Q3 24
6.5%
29.6%
Q2 24
1.6%
29.0%
Q1 24
8.1%
27.7%
Capex Intensity
IDT
IDT
PCRX
PCRX
Q4 25
1.8%
0.1%
Q3 25
1.7%
2.2%
Q2 25
1.8%
1.5%
Q1 25
1.6%
5.1%
Q4 24
1.7%
1.1%
Q3 24
1.7%
2.4%
Q2 24
1.6%
0.9%
Q1 24
1.5%
1.7%
Cash Conversion
IDT
IDT
PCRX
PCRX
Q4 25
-0.45×
Q3 25
1.84×
11.20×
Q2 25
3.49×
Q1 25
0.99×
7.37×
Q4 24
0.01×
Q3 24
0.69×
Q2 24
1.71×
2.82×
Q1 24
1.97×
5.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IDT
IDT

IDT Digital Payments$104.4M32%
IDT Global$60.2M19%
BOSS Revolution$45.7M14%
National Retail Solutions$39.3M12%
BOSS Revolution Money Transfer$36.3M11%
Net2phone$23.9M7%
Other$8.0M2%

PCRX
PCRX

EXPAREL$155.8M79%
ZILRETTA$33.0M17%
Iovera$7.0M4%

Related Comparisons